Clinical Trial Update: Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis [Phase 3]

View source ↗

Summary

An open-label extension trial of roflumilast (PDE4 inhibitor) for chronic plaque psoriasis has completed Phase 3 testing, focusing on long-term management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: Arcutis Biotherapeutics, Inc. | Conditions: Chronic Plaque Psoriasis | Phase 3 | Status: COMPLETED